Katharine A. Price

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

Jamie E. Chaft, Valerie W. Rusch, Michelle S. Ginsberg et al. · Journal of Thoracic Oncology · 2013 · 121 citations · Full text

Medicine, Oncology, Chemotherapy +14

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

Katharine A. Price, Christopher G. Azzoli, Lee M. Krug et al. · Journal of Thoracic Oncology · 2010 · 93 citations · Full text

Medicine, Oncology, Pharmacology +10

Detectable Postoperative Circulating Tumor Human Papillomavirus DNA and Association with Recurrence in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma

David M. Routman, Sunil Kumar, Bisham S. Chera et al. · International Journal of Radiation Oncology*Biology*Physics · 2022 · 79 citations

Medicine, Oncology, Molecular Oncology +9

MC1675, a Phase III Evaluation of De-Escalated Adjuvant Radiation Therapy (DART) vs. Standard Adjuvant Treatment for Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma

Katharine A. Price, Eric J. Moore, Samir H. Patel et al. · International Journal of Radiation Oncology*Biology*Physics · 2021 · 54 citations

Medicine, Oncology, Radiation Oncology +13

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study

Paul V. Viscuse, Katharine A. Price, Joaquín J. García et al. · Frontiers in Oncology · 2019 · 53 citations · Full text

Medicine, Oncology, Chemotherapy +13